Amylyx (AMLX) director Paul Fonteyne receives grant of 24,372 stock options

Rhea-AI Filing Summary

Amylyx Pharmaceuticals director Paul R. Fonteyne received a grant of stock options covering 24,372 shares of common stock. The options have an exercise price of $14.31 per share and were awarded at no cost to him as compensation.

These options vest in full on the earlier of June 4, 2027 or the date of the next annual meeting, as long as he continues serving the company through that date. After this grant, he holds 24,372 stock options directly.

Insider Trade Summary

1 transaction reported

Mixed 1 txn

Insider FONTEYNE PAUL R.

Role null

Type	Security	Shares	Price	Value
Grant/Award	Stock Option (right to buy)	24,372	$0.00	--

Holdings After Transaction: Stock Option (right to buy) — 24,372 shares (Direct, null)

Footnotes (1)

1. [object Object]

Key Figures

Stock options granted: 24,372 options Exercise price: $14.31 per share Post-transaction holdings: 24,372 options +2 more

5 metrics

Stock options granted 24,372 options Grant to director Paul R. Fonteyne

Exercise price $14.31 per share Strike price for granted options

Post-transaction holdings 24,372 options Derivative securities following transaction

Option expiration June 3, 2036 Expiration date of stock options

Vesting date June 4, 2027 or next annual meeting Earlier date determines full vesting

Key Terms

Stock Option (right to buy), exercise price, expiration date, vest in full, +1 more

5 terms

Stock Option (right to buy) financial

"security_title: "Stock Option (right to buy)""

exercise price financial

"conversion_or_exercise_price": "14.3100""

The exercise price is the fixed amount at which you can buy or sell an asset, like a stock, when using an options contract. It matters because it helps determine whether exercising the option will be profitable or not, depending on the current market price. Think of it as the set price you agree on today to buy or sell later.

expiration date financial

"expiration_date": "2036-06-03T00:00:00.000Z""

The expiration date is the deadline after which a financial contract, such as an option or a futures agreement, is no longer valid or can be exercised. It matters to investors because it determines the timeframe during which they can take action or benefit from the contract, similar to how a coupon or a food item has a limited period of usefulness. Once the expiration date passes, the contract loses its value or ability to be used.

vest in full financial

"The shares subject to this option shall vest in full upon the earlier of"

annual meeting financial

"or (ii) the date of the next annual meeting, subject to the Reporting Person's continuous service"

A company's annual meeting is a yearly gathering where owners (shareholders) and the board review performance, ask questions, and vote on key matters like electing directors, approving auditor choices, and sometimes setting pay or dividend policies. For investors it matters because decisions made and votes cast can change who runs the company, influence strategy and payouts, and affect the value or direction of their investment—similar to a homeowners’ meeting where rules and leaders that shape your property’s value are decided.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Form 4 Insider Transactions: What Each Field Means →

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

FONTEYNE PAUL R.

(Last) (First) (Middle)

C/O AMYLYX PHARMACEUTICALS, INC.

55 CAMBRIDGE PARKWAY, SUITE 6W

(Street)

CAMBRIDGE MASSACHUSETTS 02142

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Amylyx Pharmaceuticals, Inc. [ AMLX ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
06/04/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (right to buy)	$14.31	06/04/2026		A		24,372		(1)	06/03/2036	Common Stock	24,372	$0	24,372	D

Explanation of Responses:

1. The shares subject to this option shall vest in full upon the earlier of (i) June 4, 2027 or (ii) the date of the next annual meeting, subject to the Reporting Person's continuous service to the Issuer through such vesting date.

	/s/ Joshua B. Cohen, as Attorney in Fact	06/08/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

FAQ

What did Amylyx Pharmaceuticals (AMLX) disclose about Paul R. Fonteyne in this Form 4?

Amylyx Pharmaceuticals reported that director Paul R. Fonteyne received a grant of stock options for 24,372 shares of common stock. The filing shows this as a compensation-related award rather than an open-market purchase or sale of existing shares.

How many Amylyx (AMLX) stock options were granted to Paul R. Fonteyne and at what price?

Paul R. Fonteyne was granted stock options covering 24,372 shares of Amylyx common stock. The options carry an exercise price of $14.31 per share, meaning he can buy the shares at that price once the options are vested and exercisable.

When do Paul R. Fonteyne’s Amylyx (AMLX) stock options vest according to the Form 4?

The options vest in full on the earlier of June 4, 2027 or the date of the next annual meeting. Vesting is conditioned on his continuous service to Amylyx through the applicable vesting date, as specified in the Form 4 footnote.

Is the Amylyx (AMLX) Form 4 for Paul R. Fonteyne a stock purchase or a grant?

The Form 4 reflects a grant of stock options, not a market purchase. It is coded as a grant or award acquisition, awarded at a price of $0.00 for the option itself, with an exercise price of $14.31 per underlying share.

How many Amylyx (AMLX) derivative securities does Paul R. Fonteyne hold after this Form 4 transaction?

Following the reported transaction, Paul R. Fonteyne holds 24,372 derivative securities in the form of stock options. These options each relate to one share of Amylyx common stock and are held directly, according to the ownership code in the filing.